Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LR607 plus neoadjuvant chemoimmunotherapy in resectable stage II–IIIB NSCLC
ChiCTR2600117139Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lacticaseibacillus rhamnosus LR607 in non-small cell lung cancer (NSCLC), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Major pathological response. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Lacticaseibacillus rhamnosus LR607
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117139.